Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ricolinostat - Regenacy Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ricolinostat - Regenacy Pharmaceuticals

Alternative Names: ACY-1215; ACY-63; Rocilinostat

Latest Information Update: 05 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer 3E-Regenacy Pharmaceuticals (BC Regenacy); Columbia University; Dana-Farber Cancer Institute; Regenacy Pharmaceuticals
  • Class Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Multiple myeloma
  • Phase I/II Lymphoma
  • Phase I Peripheral nervous system diseases
  • No development reported Breast cancer; Charcot-Marie-Tooth disease; Chronic lymphocytic leukaemia; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 29 Feb 2024 Celgene terminates a Phase-II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Greece, Italy (PO) due to lack of efficacy (EudraCT2014-002338-29) (NCT01997840)
  • 28 Feb 2024 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in USA (PO)
  • 10 Nov 2023 3E-Regenacy Pharmaceuticals (BC Regenacy) completes a phase I trial in Peripheral nervous system diseases in China (PO) (NCT05229042)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top